



## PRESS RELEASE

---

### ASLAN PHARMACEUTICALS TO PRESENT AT H.C. WAINWRIGHT BIOCONNECT CONFERENCE 2022

**Menlo Park, California, and Singapore, January 6, 2022**, – ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that Dr Carl Firth, CEO, is scheduled to give a company presentation at the H.C. Wainwright Bioconnect Conference on January 10, 2022. The conference will be held virtually from January 10 to January 13, 2022.

An on demand recording of the presentation will be available from January 10, 2022, at 07:00am ET in the News & Events section of ASLAN's Investor Relations website at <https://ir.aslanpharma.com/> and at the following link: <https://journey.ct.events/view/849b8055-6a56-4b5b-a566-276449282256>

**Ends**

#### Media and IR contacts

**Emma Thompson**

Spurwing Communications

Tel: +65 6206 7350

Email: [ASLAN@spurwingcomms.com](mailto:ASLAN@spurwingcomms.com)

**Ashley R. Robinson**

LifeSci Advisors, LLC

Tel: +1 (617) 430-7577

Email: [arr@lifesciadvisors.com](mailto:arr@lifesciadvisors.com)

#### About ASLAN Pharmaceuticals

ASLAN Pharmaceuticals (Nasdaq:ASLN) is a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients. ASLAN is currently evaluating ASLAN004, a potential first-in-class antibody targeting the IL-13 receptor, in atopic dermatitis, and ASLAN003, a potent oral inhibitor of DHODH, which is being developed for autoimmune disease. ASLAN has a team in Menlo Park, California, and in Singapore. For additional information please visit [www.aslanpharma.com](http://www.aslanpharma.com) or follow ASLAN on [LinkedIn](#).